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ABSTRACT
Immunosuppression is an important risk factor for leishmaniasis. We assessed the clinical 
profile, geographic distribution and prevalence of leishmaniasis in patients undergoing 
immunosuppressive therapy for dermatological, rheumatological or gastroenterological 
autoimmune diseases. We identified relevant studies in PubMed, EMBASE, Scopus, Web of 
Science and LILACS on July 3rd, 2018. We included articles that reported at least one case 
of leishmaniasis in patients undergoing immunosuppressive treatment for dermatological, 
rheumatological or gastroenterological diseases. Our protocol was registered in PROSPERO 
(CRD42018103050). We assessed the quality of the included studies with the Joanna 
Briggs Institute Critical Appraisal Tool. After the removal of duplicates, 5,431 articles 
were collected and screened. We included 138 articles; the prevalence of leishmaniasis in 
six methodologically similar studies varied from three to 1,282 cases per 100,000 patients 
using anti-TNFα drugs, but the results were significantly heterogeneous . Leishmaniasis 
in patients treated with immunosuppressive drugs is a health problem mostly reported in 
European countries bordering the Mediterranean Sea; sporadic activities, such as travelling, 
seem not to be associated with a significant risk of leishmaniasis, although effective control 
measures must always be observed.
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INTRODUCTION
Leishmaniasis is an anthropozoonosis that is caused by several flagellate 
protozoan species of the genus Leishmania and transmitted by insects of the genus 
Lutzomyia1. The World Health Organization (WHO) includes leishmaniasis among 
the six most important infectious diseases worldwide2. The disease is considered 
a public health problem in 64 countries, with 90% of cases concentrated in India, 
Bangladesh, Nepal, Sudan and Brazil3.
Immunosuppression is an important risk factor for the pathogenesis of severe 
leishmaniasis and reactivation; furthermore, it can alter the response to treatment, 
resulting in adverse outcomes1. Although human immunodeficiency virus (HIV) 
infection is the most studied example of immunosuppression, other causes of 
immunosuppression have been increasingly associated with leishmaniasis, mainly 
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due to the increasing use of immunomodulatory drugs4. 
These drugs constitute an important basis for the treatment 
of autoimmune disorders5. Immunobiologicals are a 
relatively modern class of drugs that have revolutionized 
the control of immune-mediated diseases and are widely 
used for the treatment of dermatological, rheumatological 
and gastroenterological conditions. These drugs specifically 
block important mediators, such as TNF-α and other 
cytokines, thereby enhancing the risk of infection and of 
leishmaniasis reactivation. 
Although the increased risk of tuberculosis was the 
initial focus regarding infections in patients treated with 
immunosuppressive drugs, there are now a substantial 
number of reports on leishmaniasis, which is usually 
diagnosed after several months of treatment4. In this context, 
we sought to develop a clinical pathway formed by questions 
that could be answered as the main objectives of this review 
and that could elucidate literature gaps for further studies 
(Figure 1). Focusing on the main objectives, we proposed 
the following questions: What is the clinical profile and 
the geographic distribution of leishmaniasis in patients 
receiving immunosuppressive therapy for rheumatological, 
dermatological and gastroenterological diseases? What is 
the frequency of leishmaniasis in patients receiving these 
specific immunosuppressive therapies? To identify possible 
literature gaps, we proposed the following questions: 
do patients exposed to immunosuppressive biologicals 
have a higher risk of developing leishmaniasis than those 
under immunosuppression caused by other factors? Do 
immunosuppressed patients need specific measures to avoid 
Leishmania infection or leishmaniasis reactivation?
The main objective of the present systematic review 
was to assess the clinical profile, geographic distribution 
and prevalence of leishmaniasis in patients using 
any immunosuppressive agent for the treatment of 
rheumatological, dermatological or gastroenterological 
diseases. We also aimed to assess the existing literature 
gaps that need to be fulfilled as identified in the developed 
clinical pathway (Figure 1).
MATERIALS AND METHODS
Search strategy and selection criteria
The present protocol was registered in PROSPERO 
(CRD42018103050) on 14 August 2018. A comprehensive 
Figure 1 - Current clinical pathway for the occurrence of leishmaniasis in immunosuppressed patients.
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search of the following relevant databases was performed on 
3 July 2018: PubMed, EMBASE, Scopus, Web of Science 
and LILACS (Table 1). Grey literature (conference abstracts 
and proceedings) were included in the search. No date, 
language or method restrictions were applied. No additional 
search for grey literature was performed.
We included any article that reported at least one 
case of leishmaniasis in patients undergoing treatment 
with immunosuppressive drugs for dermatological, 
rheumatological or gastroenterological diseases, 
which are medical conditions frequently treated with 
immunobiologicals, a relatively new and widely used class 
of medication compared to conventional immunosuppressive 
agents (e.g., cyclosporine and methotrexate).
We excluded articles in which leishmaniasis occurred 
before the immunosuppressive treatment, as a result of an 
incorrect diagnosis; articles in which immunosuppression 
was not a result of treatment for a rheumatological, 
dermatological or gastroenterological disease and articles 
that diagnosed leishmaniasis by only serological or 
molecular examinations in asymptomatic patients.
Data extraction
After database searching, all the retrieved references 
were exported to EPPI-Reviewer 4 Version 4.6.4.0 (EPPI 
Centre, London, England), and duplicates were removed 
with the aid of an automatic tool included in the program. 
Two independent reviewers (PK and CG) screened the 
titles and abstracts and, for the articles selected during 
the initial screening process, the full texts were examined. 
Disagreements were resolved by a third reviewer (MC).
Two independent reviewers were responsible for data 
extraction (PK and FM). Disagreements were resolved 
by a third reviewer (CG). A data-extraction form was 
developed based on the authors’ clinical experience in the 
use of immunosuppressive agents and the current practical 
literature. Prior to data extraction, we performed a pilot data 
extraction with 10 randomly assigned articles to identify 
any possible obstacles.
Quality assessment
Case reports and case series were evaluated by two 
independent reviewers (CG and FM) using the Joanna 
Briggs Institute Critical Appraisal Tool6. Prevalence 
studies were independently evaluated (CG and FM) 
using the Joanna Briggs Institute Critical Appraisal Tool 
for prevalence studies. Disagreements were resolved by 
consensus.
Table 1 - Search strategy and databases accessed for the systematic review of the literature.
Accessed databases Search strategy
PUBMED (corticosteroid* OR methotrexate OR leflunomide OR cyclosporine OR infliximab OR adalimumab OR 
etanercept OR golimumab OR steroid* OR secukinumab OR ustekinumab OR apremilast OR abatacept 
OR azathioprine OR mycophenol* OR rituximab OR sulfasalazine OR tocilizumab OR tofacitinib OR 
certolizumab*) OR immunos* AND leish*
LILACs (corticosteroid* OR methotrexate OR leflunomide OR cyclosporine OR infliximab OR adalimumab OR 
etanercept OR golimumab OR steroid* OR secukinumab OR ustekinumab OR apremilast OR abatacept 
OR azathioprine OR mycophenol* OR rituximab OR sulfasalazine OR tocilizumab OR tofacitinib OR 
certolizumab*) OR immunos* AND leish*
SCOPUS (ALL (methotrexate) OR ALL (leflunomide) OR ALL (cyclosporine) OR ALL (infliximab) OR ALL 
(adalimumab) OR ALL (etanercept) OR ALL (golimumab) OR steroid* OR secukinumab OR ustekinumab 
OR apremilast OR abatacept OR azathioprine OR mycophenol* OR rituximab OR sulfasalazine OR 
tocilizumab OR tofacitinib OR certolizumab*) OR immunos* AND leish*
Web of Science #1 TS = (corticosteroid* OR methotrexate OR leflunomide OR cyclosporine OR infliximab OR adalimumab 
OR etanercept OR golimumab OR steroid* OR secukinumab OR ustekinumab OR apremilast OR abatacept 
OR azathioprine OR mycophenol* OR rituximab OR sulfasalazine OR tocilizumab OR tofacitinib OR 
certolizumab*)
# 2 TS= (immunos*)
# 3 #1 OR #2
#4 TI= (leish*)
#5 #3 AND #4
EMBASE #1 corticosteroid* OR methotrexate OR leflunomide OR cyclosporine OR infliximab OR adalimumab OR 
etanercept OR golimumab OR steroid* OR secukinumab OR ustekinumab OR apremilast OR abatacept 
OR azathioprine OR mycophenol* OR rituximab OR sulfasalazine OR tocilizumab OR tofacitinib OR 
certolizumab*
# 2 leish* ti.ab.kw
#3 #1 AND #2
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Data analysis
Firstly, a descriptive analysis of leishmaniasis cases 
in patients treated with immunosuppressive agents was 
performed. An epidemiological profile of the affected 
patients was created by considering the immunosuppressive 
agents used, the duration of autoimmune disease and 
the duration of immunosuppression. The geographical 
distribution of the cases was also compared to the 
endemicity in each country.
Secondly, all cross-sectional and longitudinal studies 
were evaluated. We ultimately selected studies that 
assessed the prevalence of leishmaniasis in patients under 
immunosuppression. The final model consisted of articles 
with similar methodologies and risk factor profiles. As 
leishmaniasis was a secondary outcome in most articles in 
this group, we could not associate the leishmaniasis cases 
with the duration of immunosuppression, and we could not 
calculate the incidence or the risk.
Proportions were calculated, and double arcsine 
transformations were applied to stabilize the variance. We 
calculated the overall summary proportion considering 
within- and between-study variation with the random 
effects model for the meta-analysis. Calculations were 
performed and plots were generated with the packages 
“meta”, “metafor” and “weightr” in the program RStudio 
for Mac (RStudio: Integrated Development for R, RStudio, 
Inc., Boston, MA, USA)7-9.
RESULTS
In total, 8,433 articles were initially selected from 
the referenced databases, and six additional articles were 
included after reading the references of the included full 
texts. After the removal of duplicates, the titles and abstracts 
of 5,431 articles were screened, and the full texts of 293 
studies were evaluated. Finally, 138 articles that met the 
inclusion criteria were selected (Figure 2).
Characteristics of the selected studies
Most articles (n = 124) were case reports or case series. 
Six population-based surveys of patients with leishmaniasis 
were also included. Eight articles evaluated the proportion 
Figure 2 - The flow diagram of the search and selection process of articles.
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of patients with leishmaniasis among patients receiving 
immunosuppressive agents. Sixteen studies were published as 
meeting abstracts, while the remainder were journal articles.
None of the selected articles compared the prevalence 
of leishmaniasis in immunosuppressed patients with 
a control group of immunocompetent ones, making it 
impossible to calculate the relative prevalence. In total, 
189 immunosuppressed patients developed leishmaniasis.
Leishmaniasis case characteristics
In immunosuppressed patients, the mean age at the time 
of leishmaniasis development was 51.63 years, the mean 
duration of the immunological disease was 12.09 years 
(range = 1-44 years, standard deviation (SD) = 9.20) and 
the mean duration of immunosuppression was 5.75 years 
(range = 0.1 to 30 years, SD = 6.14). Forty-one patients 
used systemic corticosteroids, 96 used immunobiologicals, 
42 used methotrexate and 3 used azathioprine (in seven 
cases, the immunosuppressive drugs were not specified). 
Most patients (n = 105) developed visceral leishmaniasis, 
65 patients developed cutaneous leishmaniasis and 
14 patients developed mucocutaneous leishmaniasis. Only 
10 patients reported having had contact with leishmaniasis 
patients or dogs known to have leishmaniasis. Considering 
the clinical picture, only 39 atypical leishmaniasis cases 
were reported. A Leishmania species known to cause 
visceral disease (Leishmania infantum) resulted in 
mucocutaneous leishmaniasis in only one case10.
Parasitological diagnostic methods were used in 
117 patients, while polymerase chain reaction (PCR) was 
necessary for diagnosis in only 25 patients. Most identified 
Leishmania species were Old World species, including 
Leishmania aethiopica (n = 2), Leishmania donovani 
(n = 15), Leishmania infantum (n = 33), Leishmania major 
(n = 3), Leishmania tropica (n = 2), Leishmania amazonensis 
(n = 1) and Leishmania braziliensis (n = 2).
Treatment usually consisted of the administration of 
liposomal amphotericin B (n = 89 cases), and pentavalent 
antimonials (n = 52 cases). Ninety-two patients were 
cured with only one course of treatment, while 22 needed 
more than one course of treatment to cure leishmaniasis. 
In 72 cases, immunosuppression was halted before 
leishmaniasis-specific treatment was administered, and 
in 34 cases, immunosuppression was resumed after 
leishmaniasis was cured.
Only 10 patients had apparent reactivation of latent 
leishmaniasis, while the vast majority (n = 112) were 
probably infected while on immunosuppressive therapy. 
Most patients were undergoing immunosuppressive 
therapy for rheumatological diseases (n = 152); 
19 immunosuppressed patients had dermatological 
conditionsand 18 had gastroenterological conditions. In 
most cases, the probable location of infection was Europe 
(n = 144), in countries bordering the Mediterranean Sea 
(Figure 3). The remaining cases occurred in the Middle 
East (n = 4), Asia (n = 1), South America (n = 10) and 
Africa (n = 15). Only 24 patients were travellers and only 
6 reported occupational risk factors (Figure 3).
Quality assessment
Regarding the eight articles11-18 that reported the 
prevalence of leishmaniasis in patients treated with 
immunosuppressants, none described the study subjects 
or settings in detail. No articles mentioned the validation 
methods used for the identification of the medical condition, 
any comparison to a known standard, or a reliable way to 
determine the domain response rate.
Prevalence evaluation
The eight articles11-18 that evaluated the prevalence of 
leishmaniasis in patients treated with immunosuppressive 
agents included 68,474 patients and 10 cases were 
reported in this population (Table 2). Eight patients 
developed leishmaniasis while taking TNF blockers11,14,17,18, 
one patient developed leishmaniasis while taking an 
interleukin-1 receptor antagonist (anakinra)15, and one 
patient developed leishmaniasis while being treated for 
dermatomyositis/polymyositis, a condition that can be 
treated with steroids, conventional immunosuppressive 
agents and/or immunobiologicals16. Considering only the 
studies (n = 3) that evaluated more than 1,000 participants, 
the prevalence of leishmaniasis in the immunosuppressed 
population ranged from 3 to 32 leishmaniasis cases per 
100,000 patients using anti-TNF drugs (Table 2).
Six articles were considered methodologically similar 
(patients using TNF-α blockers) (Table 2) and were selected 
to be included in the meta-analysis; however, a high degree 
of heterogeneity was detected (I2=76%; p<0.001). This 
heterogeneity was also detected by visual evaluation of 
the effect sizes and confidence intervals reported in each 
individual study (Figure 4). The prevalence of leishmaniasis 
in the six methodologically similar studies varied from 3 to 
1,282 cases per 100,000 patients using anti-TNF-α drugs. 
The small number of studies (n = 6) limited the publication 
bias analysis19.
DISCUSSION
Studies involving HIV-positive populations have shown 
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the devastating effects of leishmaniasis in immunosuppressed 
patients3,20. Although immunosuppressive agents provide 
relevant clinical benefits, they also increase the risk of 
infection and alter its natural history14,21. Interesting data 
were extracted from the cases of leishmaniasis selected 
in this study, and a profile of leishmaniasis in patients 
with medication-induced immunosuppression due to 
the treatment of rheumatological, dermatological and 
gastroenterological diseases. 
It is also important to elucidate whether there are 
Figure 3 - Geographical distribution of the reported leishmaniasis cases in patients with medication-induced immunosuppression.
Table 2 - The main characteristics of the eight studies that evaluated the prevalence of leishmaniasis in patients treated with 
immunosuppressive agents for rheumatological, dermatological and gastroenterological diseases.
Authors Immunosuppressor(S) Leishmaniasis Participants Cases Prevalence/100,000
Lequerre et al.15 Anakinra* Visceral 35 1 2,857
Garcia-Vidal et al.13 Infliximab* Visceral 94 1 1,064
Salmon-Ceron et al.18 Anti-TNF* Visceral and 
cutaneous
57,711/year 2 3
Pérez-Sola et al.14 Anti-TNF Cutaneous 6,969 2 14
Ersozlu Bozkirli et al.12 Anti-TNF Cutaneous 142 1 704
Marie et al.16 Steroids, methotrexate, 
immunobiologicals*
Cutaneous 279 1 358
Cobo-Ibáñez et al.11 Anti-TNF Visceral 3,166 1 32
Rubio et al.17 Remsima* 78 1 1,282
Total 68,474 10 15
*Reported co-administration of steroids; TNF = Tumour necrosis factor.
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differences in the types and rates of leishmaniasis in 
patients with different autoimmune conditions. Different 
underlying pathogenic mechanisms may impair different 
immune pathways, leading to varying degrees of infection 
severity11. Our results showed that the disease generally 
developed after > 5 years of immunosuppression and 
after 10 years of disease, although earlier development 
occurred in some cases. The majority of reports involved 
patients with rheumatological conditions that usually 
required relatively strong immunosuppression, including 
the associated use of corticosteroids. It seems clear that 
chronic and strong perturbations in immune function 
caused by a combination of immunosuppressors, including 
lymphocyte and neutrophil dysfunction, defective cell-
mediated immunity, and decreased immunoglobulin and 
cytokine production, play important roles in predisposing 
patients to infections13,18.
In contrast to our expectations (Figure 1), most 
leishmaniasis cases exhibited a typical clinical presentation 
and responded well to the first course of treatment. 
This result can be explained by a greater-than-expected 
frequency of typical cases, as observed in Leishmania/
HIV coinfection, but it does not exclude the hypothesis 
that the number of atypical leishmaniasis cases can be 
higher in immunosuppressed patients than in the general 
population. Unfortunately, this cannot be confirmed by 
the existing literature because no controlled studies were 
found. Almost all the articles referenced the immediate 
suspension of immunosuppressive agents after the 
diagnosis of leishmaniasis, although the reintroduction 
of immunobiologicals after leishmaniasis was cured was 
associated with a low frequency of disease reactivation.
The geographical distribution of the included cases 
also showed unexpected results. The countries that most 
often reported leishmaniasis in patients with medication-
induced immunosuppression were considerably different 
from the global picture of this neglected disease in the 
general population (Figure 3). While leishmaniasis in 
Europe accounts for only 2% of all leishmaniasis cases 
in the world, our article showed that 76.19% of the cases 
of leishmaniasis in immunosuppressed individuals were 
reported in Europe22. Chronic rheumatic conditions are 
more common in developed countries than in developing 
countries23,24, and as a consequence, European countries 
along the Mediterranean coast have more access to modern 
immunosuppressive treatments than do countries in South 
America and the Middle East, in which leishmaniasis is 
endemic. This result, although worthy of attention, must 
be interpreted with caution because European countries 
also have better established monitoring systems, registry 
systems and publication capacity than South American 
and African countries, and possible publication bias 
might exist. Unfortunately, the funnel plot evaluation was 
limited because of the low number of methodologically 
similar articles. The absence of a deeper search for grey 
literature may have contributed to this limitation, although 
it is probable that no high-quality studies would have been 
found.
The clinical profile and the geographical distribution 
of cases, in addition to the fact that reactivation occurred 
in a minority of cases and that few infected patients were 
travellers, calls attention to an important epidemiological 
conclusion. Patients who develop leishmaniasis during 
medication-induced immunosuppression have usually 
lived in an endemic region for a long time. Those 
patients are usually exposed to repeated bites while under 
immunosuppression, enhancing their chances of developing 
the disease. This may be reassuring for immunosuppressed 
patients who seek a better quality of life, as it is likely 
that sporadic leisure and travel activities in leishmaniasis-
endemic regions are not associated with a significant risk 
of leishmaniasis. However, precautionary advice, such as 
Figure 4 - A forest plot showing the effect sizes and confidence intervals of the six methodologically similar studies that assessed 
the occurrence of leishmaniasis in patients using TNF-α inhibitors. The visual and statistical evaluations showed substantial 
heterogeneity, making the pooled results unreliable. CI = Confidence intervals.
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avoiding peak vector activity hours and the use of protective 
clothing, must always be observed.
Only eight articles evaluated the prevalence of 
leishmaniasis in patients with medication-induced 
immunosuppression, with a total at-risk population of 
68,474. Six studies evaluated patients using anti-TNF 
immunobiologicals (n=68,160 at risk). Other factors were 
not evaluated because all the articles reported leishmaniasis 
as a secondary outcome, meaning that important gaps 
intended to be filled by this review still exist (Figure 1). This 
may explain why most articles were scored as “unclear” 
with regard to the validation methods used, identification of 
the condition and response rate measurement in the reported 
quality assessment evaluation. Additionally, we could 
not evaluate the relative risk of leishmaniasis in patients 
with medication-induced immunosuppression because no 
controlled study was included.
In the present study, we conclude that leishmaniasis 
in patients with medication-induced immunosuppression 
is a health problem due to the severity of the disease. 
This condition is reported more frequently in Europe than 
elsewhere and probably needs specific control measures. 
Although sporadic activities in endemic regions seem 
not to be associated with a significantly increased risk of 
leishmaniasis, patients’ education and environmental control 
are essential prevention measures, which must be reinforced 
for patients living in endemic areas for leishmaniasis. These 
measures may enhance the safety of immunosuppression, 
especially for rheumatological conditions that usually 
combine anti-TNF therapy with corticosteroids. 
We can also conclude that important literature gaps 
still exist. Studies that specifically seek to analyse 
leishmaniasis in patients under immunosuppression in 
large populations (>1,000) must be performed to answer 
the remaining questions. These questions including 
the magnitude of risk of developing leishmaniasis in 
patients under immunosuppression and the measures 
that immunosuppressed patients should take to avoid 
leishmaniasis.
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